Outcome measures in psoriatic arthritis

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2262-2269

  Gladman, Dafna D ^a,b,p   Mease, Philip J ^c,d,e   Krueger, Gerald ^f   Van Der Heidje, Désirée M F M ^g   Antoni, Christian ^h   Helliwell, Philip S ^h   Kavanaugh, Arthur F ⁱ   Nash, Peter ^j,k   Ritchlin, Christopher T ^l,m   Strand, C Vibeke ⁿ   Taylor, William ^o  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Rheumatology Associates   (United States)

^d Swedish Hospital Medical Center   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Nambour Hospital   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l Department of Medicine ^*  (Australia)

^m UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁿ STANFORD UNIVERSITY   (United States)

^o UNIVERSITY OF OTAGO   (New Zealand)

^p TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

Assessment instruments; Core set; Outcomes; Psoriasis; Psoriatic arthritis

Indexed keywords

ALEFACEPT; C REACTIVE PROTEIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; PLACEBO;

ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTICENTER STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; SKIN DISEASE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ARTHRITIS, PSORIATIC; HUMANS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 27744441694     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Wright V, Moll JMH. Seronegative polyarthritis. Amsterdam: North Holland Publishing; 1976.
2. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS, editors. Textbook of rheumatology. 6th ed. Philadelphia: W.B. Saunders; 2001:1071-9.
3. Gladman DD. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003;33:29-37.
4. Mease PJ. Current treatment of psoriatic arthritis. Rheum Dis Clin North Am 2003;29:495-511.
5. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis. A review of currently available measures. Arthritis Rheum 2004;50:24-35.
6. Taylor WJ. Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods. Ann Rheum Dis 2005;64 Suppl 2:ii110-2.
7. Gladman DD. Consensus exercise on domains in psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii113-4.
8. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
10. van Gestel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
11. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
12. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
13. Antoni C, Kavanaugh A, Kirkham B, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. Arthritis Rheum 2002;46 Suppl:S381.
14. Antoni C, Kavanaugh A, Kirkham B, et al. The one year results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. Arthritis Rheum 2003;48 Suppl:S285.
15. Kaltwasser JP, Nash P, Gladman D, et al, for the TOPAS Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004;50:1939-50.
16. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis - clinical and laboratory analysis of 220 patients. Q J Med 1987;62:127-41.
17. Husted JA, Gladman DD, Farewell VT, Cook R. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151-8.
18. Mease PJ, Gottlieb AB, Wanke SL, et al. Sustained improvement in activities of daily living in patients with psoriatic arthritis treated with etanercept [abstract]. Arthritis Rheum 2003;49 Suppl:S167.
19. Husted JA, Gladman DD, Cook RJ, Farewell VJ. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998;25:2146-55.
20. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9.
21. van der Heijde D, Sharp J, Wassenberg S, Gladman D. Imaging: A review of scoring methods in psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii61-4.
22. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998;37:760-5.
23. Wassenberg S, Fischer O, Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z Rheumatol 2001;60:156-66.
24. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis Rheum 1971;14:706-20.
25. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.
26. Antoni C, Kavanaugh A, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Clinical Trial (IMPACT): results of radiographie analyses after 1 year [abstract]. Arthritis Rheum 2004;50 Suppl:S450.
27. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a newretinoid. Dermatologica 1978;157:238-44.
28. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA) and Lattice System Psoriasis Global Assessment (LS-PGA). J Am Acad Dermatol 2004;51:563-9.
29. Krueger GG. The NPF Psoriasis Score. The National Psoriasis Foundation Psoriasis Forum 1999;5(4).
30. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
31. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003;139:459-64.